Wuhan Healthgen Biotechnology Corp Class ASSE: 688765

"WUHAN HEALTHGEN BIOTECHNOLOGY CORP."2026 Semi-annual Continuous Supervision and Guidance Follow-up Report of GUOTAI HAITONG SECURITIES CO., LTD. on WUHAN HEALTHGEN BIOTECHNOLOGY CORP.

Sep 11, 2026 · Issued by Wuhan Healthgen Biotechnology Corp Class A via Shanghai Stock Exchange

Filed with SSE · Sep 11, 2026

2026 Semi-annual Continuous Supervision and Guidance Follow-up Report of GUOTAI HAITONG SECURITIES CO., LTD. on WUHAN HEALTHGEN BIOTECHNOLOGY CORP.

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Company analysis

Earlier from Wuhan Healthgen Biotechnology Corp Class A

"WUHAN HEALTHGEN BIOTECHNOLOGY CORP."Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug IndustrySep 9
"WUHAN HEALTHGEN BIOTECHNOLOGY CORP."Semi-annual Report for 2026Aug 27
"WUHAN HEALTHGEN BIOTECHNOLOGY CORP."Announcement on Listing and Trading of Certain Restricted Shares from Offline Placement in the Initial Public OfferingJul 21
"WUHAN HEALTHGEN BIOTECHNOLOGY CORP."Announcement on Attending the 2026 Collective Reception Day for Investors of Listed Companies in Hubei Jurisdiction and 2025 Annual Performance BriefingJul 2

All Wuhan Healthgen Biotechnology Corp Class A news releases